Latest Breaking News On - Michael dougan - Page 5 : comparemela.com

Credit: Getty Images. HealthDay News — For ambulatory patients with mild or moderate COVID-19 who are at high risk for progression to severe disease, bamlanivimab plus etesevimab infusion leads to a lower incidence of COVID-19-related hospitalization and death, according to a study published online July 14 in the New England Journal of Medicine. Michael Dougan, MD, PhD, from Massachusetts General Hospital in Boston, and colleagues randomly assigned a cohort of ambulatory patients with mild or moderate COVID-19 at high risk for progression to severe disease to receive a single intravenous infusion of a neutralizing monoclonal-antibody combination agent (bamlanivimab and etesevimab) or placebo (518 and 517 patients, respectively) within 3 days after SARS-CoV-2 diagnosis.

United statesMichael douganEli lillyHealthday newsNew england journalMassachusetts general hospitalஒன்றுபட்டது மாநிலங்களில்மைக்கேல் டௌகந்எலி லில்லிபுதியது இங்கிலாந்து இதழ்மாசசூசெட்ஸ் ஜநரல் மருத்துவமனை